Author

N. Boechat

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M. Mattos· 3 shared A. Ferreira· 2 shared C. de Freitas· 2 shared F. Bozza· 2 shared G. Barbosa-Lima· 2 shared L. V. B. Hoelz· 2 shared M. Bastos· 2 shared P. Bozza· 2 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

M. Mattos

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A selective adenylyl cyclase 1 inhibitor relieves pain without causing tolerance

G. Giacoletti, T. Price, L. V. B. Hoelz, A. Shremo Msdi, K. Vazquez-Falto, T. V. Amorim Fernandes, V. Santos de Pontes, H. Wang, N. Boechat, A. Nornoo, T. Brust

This study shows that ST034307, a selective AC1 inhibitor, relieves pain in mouse models without causing tolerance.

bioRxiv · Jun 23, 2021Pharmacology & Toxicology

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

C. Q. Sacramento, N. Fintelman-Rodrigues, J. R. Temerozo, A. d. P. D. Da Silva, S. da Silva Gomes Dias, A. C. Ferreira, C. d. S. da Silva, M. Mattos, C. R. R. Pao, C. S. de Freitas, V. Cardoso Soares, L. V. B. Hoelz, T. V. A. Fernandes, F. S. C. Branco, M. M. Bastos, , T. M. L. Souza

This study evaluates the antiviral activity of daclatasvir and sofosbuvir against SARS-CoV-2 in vitro, showing inhibition of viral replication and associated pathologies.

bioRxiv · Jun 15, 2020 · PreprintMicrobiology

Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication

A. Ferreira, P. Reis, C. de Freitas, C. Queiroz, L. Villas Boas Hoelz, M. Bastos, M. Mattos, E. Correia Loiola, P. Trindade, Y. Rangel Vieira, G. Barbosa-Lima, H. de Castro Faria Neto, N. Boechat, S. Rehen, K. Bruning, , T. Souza

This study shows sofosbuvir inhibits chikungunya virus replication in cell cultures and animal models, with selectivity over ribavirin and efficacy in vivo.

bioRxiv · Jul 2, 2018Microbiology

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo

C. de Freitas, L. Higa, C. Sacramento, A. Ferreira, P. Reis, R. Delvecchio, F. Monteiro, G. Barbosa-Lima, Y. Vieira, M. Mattos, L. Hoelz, R. Leme, M. Bastos, F. Bozza, P. Bozza, , T. Souza

This study shows that sofosbuvir inhibits Yellow fever virus replication in vitro and protects mice from infection, suggesting it as a potential therapeutic option.

bioRxiv · Feb 15, 2018Microbiology